PP2A

PP2A
Opabinia regalis · CC BY-SA 4.0 · source
Name	Protein phosphatase 2A
Ec number	3.1.3.16
Other names	PP2A
Subunits	catalytic C subunit, scaffold A subunit, regulatory B subunits

PP2A

Introduction

Protein phosphatase 2A is a major serine/threonine phosphatase implicated in cellular regulation across eukaryotes, interacting with signaling networks that include nodes characterized in studies of MAPK signaling pathway, PI3K–AKT signaling, Wnt signaling pathway, mTOR signaling, and TGF-β signaling. Research groups from institutions such as Harvard University, Max Planck Society, Cold Spring Harbor Laboratory, Stanford University, and Massachusetts Institute of Technology have contributed to elucidating its roles in processes described in reports linked to Cell (journal), Nature (journal), Science (journal), The EMBO Journal, and Journal of Biological Chemistry.

Structure and Subunit Composition

The holoenzyme is a heterotrimer composed of a catalytic C subunit, a scaffold A subunit, and one of several regulatory B subunits; structural studies from teams at European Molecular Biology Laboratory, European Synchrotron Radiation Facility, and Brookhaven National Laboratory resolved interfaces using crystallography methods similar to those applied in analyses of hemoglobin, DNA polymerase I, and ribosome. The scaffold A subunit exhibits HEAT repeats homologous to domains described in protein phosphatase 1, importin, and PP4, while the B-family diversity (B, B', B'' families) parallels regulatory heterogeneity seen in complexes studied by researchers at Cold Spring Harbor Laboratory and EMBL. Mutagenesis and structural comparisons reference techniques used in investigations of p53, BRCA1, and ATM to map binding surfaces and conformational dynamics.

Regulation and Post-translational Modifications

Regulation occurs via methylation of the catalytic subunit, phosphorylation events, and association with endogenous inhibitors such as those related to regulatory proteins characterized in reports from Salk Institute and Howard Hughes Medical Institute. Enzymatic control involves methyltransferases and demethylases akin to those described for DNA methyltransferase 1, and phosphorylation patterns intersect with kinases including CDK1, PKA, PKC, and GSK3B; studies referencing enzymatic regulation cite methods used in research on SRC and ABL1. Inhibitors and modulating proteins identified by teams at University of Cambridge, Columbia University, and Yale University are often compared to regulators in pathways involving NF-κB, β-catenin, and c-Myc.

Biological Functions and Signaling Pathways

PP2A participates in cell cycle control, apoptosis, and developmental signaling pathways often studied in model systems such as Saccharomyces cerevisiae, Drosophila melanogaster, Caenorhabditis elegans, and Mus musculus. Functional interactions map to checkpoints regulated by CDK1, Wee1, and Cdc25 and intersect with tumor suppressor networks including RB1 and TP53. PP2A modulates phosphorylation states in pathways investigated alongside Notch, Hedgehog, and Hippo, with phenotypic consequences studied in publications from Johns Hopkins University and University of Oxford.

Role in Disease and Therapeutic Targeting

Dysfunction and mutation of regulatory subunits have been implicated in oncogenesis, neurodegeneration, and resistance to targeted therapies; clinical and preclinical studies from Memorial Sloan Kettering Cancer Center, Dana–Farber Cancer Institute, Mayo Clinic, and pharmaceutical companies such as Roche and Pfizer explore PP2A-directed strategies. Alterations are discussed in the context of cancers with mutations in KRAS, PIK3CA, and EGFR and in neurodegenerative disorders alongside proteins like tau protein and alpha-synuclein. Therapeutic approaches include small molecules, peptide modulators, and strategies described in trials registered by organizations such as National Institutes of Health and collaborative consortia patterned after drug development pipelines at GlaxoSmithKline and Novartis.

Experimental Methods and Assays

Biochemical assays derive from canonical techniques used in work on phosphatases like PTEN and PP1 and employ phosphatase activity assays, co-immunoprecipitation, mass spectrometry, and cryo-electron microscopy similar to workflows at Max Planck Institute for Biophysical Chemistry. Genetic approaches use CRISPR-Cas9 platforms pioneered at Broad Institute and RNAi methodologies developed at Whitehead Institute. Model organism genetics borrow experimental paradigms from studies involving zebrafish, Xenopus laevis, and Arabidopsis thaliana to assess developmental phenotypes, while clinical proteomics leverages platforms associated with The Cancer Genome Atlas and Clinical Proteomic Tumor Analysis Consortium.

Evolution and Comparative Biology

Evolutionary analyses compare PP2A subunits across eukaryotic lineages, integrating phylogenetic methods used in studies of yeast, plants, and metazoans; comparative genomics efforts led by groups at Wheat Initiative-style consortia and databases curated by Ensembl and UniProt trace conservation of catalytic motifs shared with phosphatases characterized in the genomes of Drosophila melanogaster, Caenorhabditis elegans, Arabidopsis thaliana, and Homo sapiens. Patterns of duplication and divergence mirror evolutionary scenarios discussed in reviews from Royal Society publishing and comparative studies coordinated through centers like Wellcome Sanger Institute.

Category:Protein phosphatases